What Is Lupus Anticoagulant and How Does It Cause Clots?

Lupus anticoagulant is an autoantibody that slows clotting in a test tube but raises the risk of dangerous blood clots inside the body. That contradiction is not just confusing for patients who hear the name for the first time; it has puzzled researchers for more than half a century. The antibody targets phospholipids and phospholipid-binding proteins that coagulation reactions depend on, and while removing those targets from a lab reaction makes blood take longer to clot, the same antibody triggers a cascade of pro-clotting effects on living cells and tissues that a glass tube cannot replicate.

Why the Name Is Misleading

The term “lupus anticoagulant” was coined decades ago when researchers noticed that plasma from certain lupus patients made standard clotting tests run long, as though the blood contained an anticoagulant. The name stuck, but it is wrong on two counts. First, the antibody is not exclusive to lupus. It shows up in people with other autoimmune diseases, infections, certain medications, and sometimes in people with no underlying illness at all. Second, it is not really an anticoagulant. Inside the body it does the opposite, promoting clot formation. The “anticoagulant” label describes only what happens in a laboratory test, not what happens in your veins and arteries.¹

The Lab Paradox Explained

Clotting tests work by adding reagents to a plasma sample and timing how long it takes for a clot to form. Many of those reactions require phospholipid surfaces as a scaffold where clotting factors assemble. Lupus anticoagulant antibodies bind to phospholipid-associated proteins, effectively crowding out the clotting factors that need those surfaces. With fewer docking sites available, the reaction stalls and the clotting time stretches out.²

The two main antibody targets are beta-2-glycoprotein I and prothrombin. Antibodies against beta-2-glycoprotein I work by binding that protein and then interfering directly with factor V, one of the key clotting factors. Antibodies against prothrombin take a different route: they form complexes that compete with another clotting factor for space on the phospholipid surface, blocking it from reaching its reaction partners.³ Both mechanisms slow down the test-tube reaction, but neither tells you what the antibodies actually do in a living bloodstream.

How the Same Antibody Promotes Clots In Vivo

The laboratory paradox exists because a clotting test is a stripped-down version of what happens in the body. Living blood vessels have endothelial cells, platelets, complement proteins, and a natural braking system for clotting that a test tube does not contain. Lupus anticoagulant antibodies mess with several of those living systems at once, and the net result is a hypercoagulable state.⁴

One of the most important mechanisms involves the protein C system, the body’s main natural anticoagulant pathway. Activated protein C normally breaks down factor Va, shutting off clotting before it goes too far. Research has shown that lupus anticoagulant antibodies prevent activated protein C from doing that job. They block the assembly of the molecular complex that protein C needs to destroy factor Va, even when protein S levels are normal. The result is that factor Va stays active longer than it should, and clotting runs unchecked.⁵ This acquired resistance to activated protein C has been confirmed as a genuine in-vivo effect, not just a test-tube artifact.⁶

On top of disabling the braking system, the antibodies also step on the accelerator. Serum from patients with lupus has been shown to ramp up the procoagulant activity of endothelial cells, the cells lining blood vessel walls.⁷ And in patients with systemic lupus, the complement system adds another layer: complement activation products deposit on platelets and interact with coagulation pathways, further tilting the balance toward clotting.⁸

Where Clots Tend to Form

Lupus anticoagulant is associated with both venous and arterial clots. Deep vein thrombosis in the legs is one of the more common presentations, but pulmonary embolism, stroke, and heart attack all occur at rates higher than you would expect in people carrying these antibodies. In one study of patients with primary Sjögren’s syndrome who tested positive for antiphospholipid antibodies, lupus anticoagulant stood out as a marker for stroke, and the mean age at stroke was just 35.⁹ The antibody’s ability to drive both venous and arterial events distinguishes it from many other clotting disorders, which tend to favor one vascular bed over the other.

A skin finding called livedo reticularis, a mottled, purplish, net-like discoloration, is also significantly more common in people who test positive. A meta-analysis found that lupus anticoagulant positivity roughly quadrupled the odds of livedo compared with people who tested negative.¹⁰ Livedo is thought to reflect tiny clots or inflammation in small skin vessels, and while it is not dangerous on its own, it can signal an underlying prothrombotic state.

Pregnancy Complications

Lupus anticoagulant does not only cause clots in large vessels. It can devastate a pregnancy by attacking the placenta. In one early case series, patients carrying the antibody experienced spontaneous abortions or fetal deaths in nearly all of their pregnancies.¹¹ The damage has been traced to the placental blood supply: spiral arteries in the placenta can develop thickened walls, fibrinoid necrosis, and intraluminal clots. One postulated mechanism is that the antibody suppresses production of prostacyclin, a molecule that normally keeps small blood vessels open and prevents clots from forming on vessel walls.¹²

Beyond thrombosis, the antibody seems to harm the placenta at a cellular level. Lab work has shown that serum containing lupus anticoagulant increases trophoblast cell death, slows trophoblast proliferation, and reduces the invasion of trophoblast cells that is necessary for a healthy placenta to establish itself. Heparin treatment was able to counteract some of these effects, which helps explain why heparin combined with low-dose aspirin has become standard therapy for pregnant women with antiphospholipid syndrome.¹³

Who Has Lupus Anticoagulant

Despite the name, lupus is only one of many conditions in which the antibody appears. It shows up in antiphospholipid syndrome (APS), which can occur on its own (primary APS) or alongside autoimmune diseases like lupus (secondary APS). A European multicenter study found that patients with primary APS and those with APS plus lupus had largely similar clinical profiles when it came to clotting events, though heart valve disease, low complement levels, and certain blood count abnormalities were more common in the lupus group.¹⁴

Antiprothrombin antibodies, one of the two main drivers of lupus anticoagulant, have been found in close to half of patients with autoimmune disease, compared with about 5% of healthy controls. Those antibodies were independently linked to arterial thrombosis.¹⁵

In children, lupus anticoagulant sometimes turns up incidentally when a prolonged clotting time is found during workup for a suspected bleeding problem. One pediatric study found a preliminary incidence of about 21% in children being evaluated for bleeding disorders, and the antibody resolved and clotting times normalized in about 90% of those cases.¹⁶ Transient lupus anticoagulant in children is often triggered by viral infections and rarely causes clinical problems.

Testing Pitfalls

Diagnosing lupus anticoagulant is harder than it sounds, because the tests are finicky and easily thrown off by common medications. The basic approach involves showing that a clotting time is prolonged, that mixing the patient’s plasma with normal plasma does not correct it (ruling out a simple factor deficiency), and that the prolongation depends on phospholipid concentration. Each of those steps has room for error.

Anticoagulant medications are the biggest headache. Direct oral anticoagulants can cause both false-positive and false-negative results. Rivaroxaban tends to push results toward a false positive, while apixaban can mask a true positive.¹⁷ This is a real clinical dilemma, because the patients most likely to be tested for lupus anticoagulant are often already on blood thinners for a recent clot.¹⁸ Expert guidelines generally recommend testing before starting anticoagulation or during a supervised pause, but that is not always practical.

Even the mixing test, which is supposed to distinguish an inhibitor from a factor deficiency, has variable performance depending on the specific assay used and how the cutoff is set.¹⁹ A single positive test is not considered sufficient for diagnosis. International guidelines require confirmation on a second sample taken at least 12 weeks later, because transient positivity is common.

Persistent Versus Transient Positivity

Whether lupus anticoagulant sticks around matters a lot for your risk. A longitudinal study found that about 56% of patients with antiphospholipid antibodies maintained persistent profiles over time, while 44% were transient. Patients with persistent antibodies had roughly two and a half times the odds of clinical recurrence compared with those whose antibodies disappeared.²⁰ People who tested positive for all three major antiphospholipid antibody types simultaneously (so-called “triple positivity”) were overwhelmingly likely to remain persistent.

What complicates risk prediction is that even people who appear to become negative often flip positive again. In one cohort, about two-thirds of patients who initially turned negative had a positive result again within a few years, with a median time to re-positivity of about one year.²¹ This is why many specialists are cautious about stopping anticoagulation even after a single negative retest.

How Risky Is an Isolated Positive Test

Not everyone who tests positive for lupus anticoagulant carries the same clot risk. Some people are positive for multiple antiphospholipid antibody types, while others test positive only for lupus anticoagulant. You might expect that “isolated” positivity would be lower risk, but the data tell a different story. One study found that isolated lupus anticoagulant positivity was strongly associated with vascular thrombosis, with odds over seven times higher than in people without the antibody. That association was actually stronger than for triple-positive samples, which had about four times the odds.²² The takeaway is that lupus anticoagulant should not be dismissed as a minor lab curiosity, even when it is the only antiphospholipid antibody detected.

Treatment After a Clot

Once someone with lupus anticoagulant or antiphospholipid syndrome has had a blood clot, long-term anticoagulation is usually recommended. Warfarin has been the backbone of treatment for decades. A randomized trial comparing moderate-intensity warfarin (target INR 2.0 to 3.0) to high-intensity warfarin (target INR 3.1 to 4.0) found that high-intensity treatment was not better at preventing recurrent clots and did not cause more bleeding, though the study was small. The low recurrence rate in the moderate-intensity group led researchers to conclude that a target INR of 2.0 to 3.0 is appropriate for most patients.²³

The bigger question in recent years has been whether newer direct oral anticoagulants can replace warfarin in this population. The answer, so far, is that they generally should not. A meta-analysis of randomized trials found that patients with antiphospholipid syndrome who took direct oral anticoagulants had more than five times the odds of arterial clots, especially strokes, compared with those who stayed on warfarin.²⁴ Another meta-analysis confirmed the signal, with a similarly elevated risk of arterial events in the direct oral anticoagulant group.²⁵ As a result, most expert guidelines now recommend sticking with warfarin for antiphospholipid syndrome, particularly in patients with arterial events or triple positivity.

Prevention Before a First Clot

For people who carry antiphospholipid antibodies but have never had a clot, the question is whether preventive treatment makes sense. A meta-analysis of observational studies found that low-dose aspirin cut the risk of a first thrombotic event by about half in asymptomatic carriers, with a similar benefit seen in patients with lupus and in those with obstetric antiphospholipid syndrome.²⁶ European guidelines recommend daily low-dose aspirin (75 to 100 mg) for asymptomatic carriers with a high-risk antibody profile, noting that the evidence is largely observational but the potential benefit is clear and the risk of aspirin is low.²⁷

Controlling traditional cardiovascular risk factors, such as high blood pressure, smoking, high cholesterol, and diabetes, is also considered essential in anyone carrying the antibodies, because those factors compound the clotting risk.

Perioperative Considerations

Surgery creates a practical dilemma for people on long-term warfarin for antiphospholipid syndrome. Stopping the blood thinner raises the risk of a clot, but continuing it raises the risk of surgical bleeding. The usual strategy is to “bridge” with injectable heparin around the procedure. In a large study of perioperative management in these patients, about 43% of warfarin interruptions involved therapeutic-dose heparin bridging before surgery, and a common pattern was to de-escalate to a lower dose after the operation. Patients who were triple-positive or had a history of arterial clots were far more likely to receive the higher-intensity bridging.²⁸ There is no one-size-fits-all approach; the decision depends on the antibody profile, the type of surgery, and the patient’s clotting history.